Business Context and Reporting Period
This Form 8-K filing by Pacific Biosciences of California, Inc. (PACB) was submitted on February 7, 2020. The report discloses a material corporate governance event regarding the departure of a principal officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statement data.
Material Changes
The primary material change reported is the announced retirement of Michael Phillips, Senior Vice President of Research and Development. His departure is effective April 1, 2020. The company explicitly states that this retirement is not the result of any material disagreement regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlook, or specific risk factors beyond the standard disclosure of the executive departure. The event is presented as a planned retirement rather than an unexpected contingency.
Investor Verification Checklist
- Verify the effective date of Michael Phillips' retirement (April 1, 2020).
- Confirm the absence of any material disagreement between the departing executive and the company.
- Review the attached press release (Exhibit 99.1) for details on succession planning for the R&D role.
- Check subsequent filings for the appointment of a replacement Senior Vice President of Research and Development.